T-DXd vs TPC in patients with HER2-low unresectable and/or metastatic BC in Asian subgroup: Results of DESTINY-Breast04

被引：0
|
作者：
Tsurutani, Junji [1 ]
Modi, Shanu [2 ]
Sohn, Joo Hyuk [3 ]
Tokunaga, Eriko [4 ]
Niikura, Naoki [5 ]
Park, Yeon Hee [6 ]
Lee, Keun Seok [7 ]
Chae, Yee Soo [8 ]
Wang, Xiaojia [9 ,10 ]
Li, Wei [11 ]
Im, Seock-Ah [12 ]
Xu, Binghe [13 ]
Lu, Yen-Shen [14 ]
Gambhire, Dhiraj [15 ]
Nishijima, Soichiro [16 ]
Nishiyama, Yuji [16 ]
Sugihara, Masahiro [16 ,17 ]
机构：
[1] Showa Univ, Adv Canc Translat Res Inst, Tokyo, Japan
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Yonsei Canc Ctr, Seoul, South Korea
[4] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[5] Tokai Univ, Hiratsuka, Kanagawa, Japan
[6] Samsung Med Ctr, Seoul, South Korea
[7] Natl Canc Ctr, Gyeonggi Do, South Korea
[8] Kyungpook Natl Univ, Chilgok Hosp, Daegu, South Korea
[9] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou, Peoples R China
[10] Chinese Acad Sci, Inst Canc & Basic Med, Hangzhou, Peoples R China
[11] 1st Hosp Jilin Univ, Changchun, Peoples R China
[12] Seoul Natl Univ Hosp, Seoul, South Korea
[13] CAMS, Canc Inst & Hosp, Beijing, Peoples R China
[14] Natl Taiwan Univ Hosp, Taipei, Taiwan
[15] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[16] Daiichi Sankyo Co Ltd, Tokyo, Japan
[17] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2-2
引用
收藏
页码：S1379 / S1379
页数：1
相关论文
共 50 条
  • [41] Multicenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in patients with HER2-low metastatic breast cancer (MBC)
    Huppert, Laura
    Mahtani, Reshma
    Fisch, Samantha
    Dempsey, Naomi
    Premji, Sarah
    Raimonde-Taylor, Angelina
    Jacob, Saya
    Quintal, Laura
    Chien, Jo
    Melisko, Michelle
    Sandoval-Leon, Ana
    Carcas, Lauren
    Ahluwalia, Manmeet
    Harpalani, Natasha
    Hoppenworth, Jenna
    Idossa, Dame
    Rao, Ruta
    Giridhar, Karthik
    Rugo, Hope
    CANCER RESEARCH, 2024, 84 (09)
  • [42] An Open-label, Interventional, Multicenter Study of Trastuzumab Deruxtecan Monotherapy in Patients With Unresectable and/or Metastatic HER2-Low or HER2 Immunohistochemistry 0 Breast Cancer: DESTINY-Breast15
    Modi, Shanu
    Salgado, Roberto
    Guarneri, Valentina
    Alagappan, Divi
    Dennis, Natalie
    Newell, Amy Hanlon
    Boran, Aislyn
    Morsli, Ouzna
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2024, 84 (09)
  • [43] Uncovering Bystander Killing Mechanisms of Trastuzumab Deruxtecan (T-DXd): Effective Extracellular Payload Release via Cathepsin L in HER2-low Breast Cancer
    Tsao, Li-Chung
    Wang, John S.
    Ragusa, Joey
    Liu, Bushangqing
    McBane, Jason
    Spasojevic, Ivan
    Fan, Ping
    Trotter, Timothy N.
    Lyerly, Herbert Kim
    Hartman, Zachary C.
    CANCER IMMUNOLOGY RESEARCH, 2024, 12 (10)
  • [44] Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.
    Hamilton, Erika P.
    Petry Helena, Vanessa Bragaia
    Yeo, Bragaia Winnie
    Kim, Sung-Bae
    Bianchini, Giampaolo
    Yamashita, Toshinari
    Yonemori, Kan
    Inoue, Kenichi
    Curigliano, Giuseppe
    Hurvitz, Sara A.
    Cortes, Javier
    Iwata, Hiroji
    Cathcart, Jillian
    Liu, Yali
    Lee, Caleb C.
    Bako, Emarjola
    Kim, Rachel
    Im, Seock-Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [45] Trastuzumab deruxtecan (T-DXd; DS-8201) in HER2-positive (HER2+) and HER2-low expressing (HER-LE) metastatic breast cancer (MBC) with brain metastases (BM) and/or leptomeningeal carcinomatosis (LMC): DEBBRAH
    Vaz Batista, M.
    Perez-Garcia, J. M.
    Llombart Cussac, A.
    Cortez, P.
    Ruiz Borrego, M.
    De la Haba, J.
    Cejalvo, J. M.
    Racca, F.
    Servitja, S.
    Blanch, S.
    Lema, L.
    Galan Garmaje, M.
    Fernandez-Abad, M.
    Fernandez, A.
    Iranzo, V.
    Gonzalez-Santiago, S.
    Gion, M.
    Nave, M.
    Cortes, J.
    Braga, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S509 - S510
  • [46] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study
    Krop, I.
    Saura Manich, C.
    Yamashita, T.
    Park, Y. H.
    Kim, S. -B. K.
    Tamura, K.
    Andre, F.
    Iwata, H.
    Ito, Y.
    Tsurutani, J.
    Sohn, J.
    Denduluri, N.
    Perrin, C.
    Aogi, K.
    Tokunaga, E.
    Im, S. -A.
    Lee, K. S.
    Hurvitz, S.
    Cortes, J.
    Lee, C.
    Chen, S.
    Zhang, L.
    Shahidi, J.
    Yver, A.
    Modi, S.
    SWISS MEDICAL WEEKLY, 2020, : 25S - 25S
  • [47] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
    Janne, Pasi A.
    Goto, Yasushi
    Kubo, Toshio
    Ninomiya, Kiichiro
    Kim, Sang-We
    Planchard, David
    Ahn, Myung-Ju
    Smit, Egbert F.
    De langen, Adrianus Johannes
    Perol, Maurice
    Pons-Tostivint, Elvire
    Novello, Silvia
    Hayashi, Hidetoshi
    Shimizu, Junichi
    Kim, Dong-Wan
    Pereira, Kaline
    Cheng, Fu-Chih
    Taguchi, Ayumi
    Cheng, Yingkai
    Goto, Koichi
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03
    Saura, Cristina
    Cortes, Javier
    Modi, Shanu
    Kim, Sung-Bae
    Hamilton, Erika P.
    Hurvitz, Sara A.
    Krop, Ian E.
    Curigliano, Giuseppe
    Iwata, Hiroji
    Im, Seock-Ah
    Herbolsheimer, Pia Maarit
    Karnoub, Maha
    Gambhire, Dhiraj
    Egorov, Anton
    Andre, Fabrice
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma
    Fuchs, C.
    Shahidi, J.
    Mathew, L.
    Qin, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2020, 31 : S150 - S150
  • [50] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03
    Krop, Ian E.
    Wildiers, Hans
    Hurvitz, Sara A.
    Cortes, Javier
    Im, Seock-Ah
    Iwata, Hiroji
    Andre, Fabrice
    Saura, Cristina
    Modi, Shanu
    Kim, Sung-Bae
    Egorov, Anton
    Mathias, Elton
    Cathcart, Jillian
    Cagnazzo, Antonio
    Cheng, Yingkai
    Park, Yeon Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345